Dexcom was issued with an FDA warning letter after issues with “manufacturing processes and quality management systems.” ...
DexCom received a warning letter from the Food and Drug Administration following inspections of two of its plants.
THE Food and Drug Administration (FDA) has launched an online application process for Certificate of Medical Device Notification (CMDN) for Class A ...
The warning letter identified issues in manufacturing processes and quality management system at Dexcom's facilities in San ...
Indian Pharmaceutical Alliance says the study relies on FDA Adverse Event Reporting System data, which captures link between ...
The FDA cited issues with DexCom’s response to prior inspection findings, known as Form 483 observations. The inspections took place at the San Diego facility between October 21 and November 7, 2024, ...
To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded ...
The company does not expect the warning letter to materially impact its manufacturing capacity, sales or ability to seek ...
and Mesa, Ariz. related to concerns about manufacturing processes and quality management systems. The FDA cited issues with DexCom's response to prior inspection findings, known as Form 483 ...
In the fast-evolving world of artificial intelligence and machine learning, the importance of rigorous quality assurance ...
Over 1.2 million medical device adverse event reports were not submitted to the US Food and Drug Administration (FDA) within the deadline set by federal regulations, finds an analysis of recent data ...
The FDA’s restraints on food ingredients are limited and relatively feeble, especially compared with those in Europe, a KFF Health News examination found.